We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

COV
NYSE
People also watch : TEL TYC BCR BAX ADT
0.00 0.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 0.00
Open 0.00
Bid 0.00 x
Ask 0.00 x
52wk Range
Day's Range 0.00 - 0.00
Volume 0
Avg Vol (3m) N/A
  • Covalon Technologies Ltd. :COV-CA: Earnings Analysis: Q2, 2016 By the Numbers : June 7, 2016
    Capital Cube 2 months ago

    Covalon Technologies Ltd. :COV-CA: Earnings Analysis: Q2, 2016 By the Numbers : June 7, 2016

    Click here to see latest analysisCovalon Technologies Ltd. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Covalon Technologies Ltd. – Pyng Medical Corp., Novadaq Technologies Inc., Neovasc Inc. and TSO3 Inc. (PYT-CA, NVDQ-US, NVC-CA and TOS-CA) that have also reported for this period.HighlightsSummary numbers: […] (Read more...) The post Covalon Technologies Ltd. :COV-CA: Earnings Analysis: Q2, 2016 By the Numbers : June 7, 2016 appeared first on CapitalCube.

  • The Wall Street Journal 2 months ago

    [$$] Medtronic Revenue Continues to Grow on Acquisition

    Medtronic gave a rosy revenue outlook for the year and reported better-than-expected growth in its fourth quarter, helped by its acquisition of Covidien.

  • TheStreet.com 5 months ago

    Medtronic Is Buying Its Way to Better Stock Health

    The medical device maker reports earnings early Tuesday.

  • Zacks 5 months ago

    Medtronic (MDT) to Report Q3 Earnings: What's in the Cards?

    Medtronic plc (MDT) is slated to report its third-quarter fiscal 2016 earnings on Mar 1, before the opening bell.

  • American City Business Journals 7 months ago

    Medtronic releases plan for spending $9.3B in freed cash

    Medtronic will return to shareholders most of the $9.3 billion in cash freed up through its acquisition of Covidien. One reason Medtronic bought Dublin-based Covidien was to free up billions in cash it had "trapped" overseas. In December, Medtronic said an internal reorganization of the combined company made $9.8 billion — $9.3 billion net of taxes — "available for general corporate purposes." Medtronic hinted at the time that it would likely return much of the cash to shareholders.

  • American City Business Journals 8 months ago

    Medtronic's Covidien deal freed up $9.3B in cash. Now, how to spend it?

    Medtronic has freed up $9.3 billion in cash that had "trapped" overseas before its acquisition of Dublin-based Covidien, but isn't revealing its plans for the haul yet. In its second-quarter earnings report, Medtronic said an internal reorganization of the combined company made $9.8 billion — $9.3 billion net of taxes — "available for general corporate purposes." The ability to access trapped cash was a key reason why Medtronic said it structured its nearly $50 billion acquisition of Covidien as a so-called tax inversion. Medtronic (MDT) has spoken generally about its plans for freed up cash in the past and officials didn't get much more specific Thursday.

  • Dividend Aristocrats Part 27: Medtronic PLC (MDT)
    Insider Monkey 8 months ago

    Dividend Aristocrats Part 27: Medtronic PLC (MDT)

    Medtronic PLC (NYSE:MDT) is ranked in the top one-third of Sure Dividend stocks using The 8 Rules of Dividend Investing.  Here’s why the company ranks well: – Below average price-to-earnings ratio of 18.3 – Below average stock price standard deviation of 24.1% – Above-average total return prospects of around 10.0% a year Among the 730 funds […]

  • Bloomberg 8 months ago

    Medtronic's Overseas Tax Move Freed Up $9.3 Billion

    Medtronic Plc’s decision to move its tax address out of the U.S. is already starting to pay dividends.

  • Zacks 8 months ago

    Medtronic Beats Q2 Earnings, Covidien Integration on Track

    Medtronic plc (MDT) reported second-quarter fiscal 2016 results with adjusted EPS of $1.03, ahead of the Zacks Consensus Estimate of $1.00.